Laurus Labs' CDMO Shift Seen Driving 24% Growth: Nuvama
Nuvama Institutional Equities initiated coverage on Laurus Labs with a 'Buy' rating and a target price of Rs 2,520, indicating a 24% upside from the current market price. The brokerage expects the company's transition from its traditional anti-retroviral (ARV) business to contract development and manufacturing (CDMO) to fuel its next growth phase.
ET Markets·




